Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, ...

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of ...

The decision was influenced by the analysis involving 160mg and 320mg doses of the therapy, indicating an unfavourable ...

Get Instant Summarized Text (Gist) An FDA-approved cancer drug that blocks the CTLA4 protein enabled immune cells to clear senescent cells in a mouse model of idiopathic pulmonary fibrosis (IPF ...

GRI Bio has announced encouraging six-week interim safety outcomes from the ongoing Phase IIa trial of the small molecule RAR ...

Idiopathic pulmonary fibrosis (IPF) causes the lung tissue to stiffen, making it harder for you to breathe. Get the facts on symptoms, life expectancy, and more.

B y this time next year, if the medical forecasts are correct, I will probably be dead, another casualty of a fatal illness that most people have never heard of: idiopathic pulmonary fibrosis (IPF ...

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. May 1 2022;205(9):e18 ...

DelveInsight’s report titled “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of burns, historical and ...